$0.18
0.00 (-0.22%)
Open$0.18
Previous Close$0.18
Day High$0.18
Day Low$0.17
52W High$3.87
52W Low$0.11
Volume—
Avg Volume71.45M
Market Cap88.24M
P/E Ratio—
EPS$-0.78
SectorBiotechnology
Analyst Ratings
Buy
14 analysts
Price Target
+15,298.9% upside
Current
$0.18
$0.18
Target
$27.41
$27.41
$18.46
$27.41 avg
$44.08
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 110.41M | 95.94M | 101.30M |
| Net Income | -388,085,880 | 13.15M | 13.02M |
| Profit Margin | -351.5% | 13.7% | 12.9% |
| EBITDA | -388,866,737 | 20.01M | 19.52M |
| Free Cash Flow | — | 11.25M | 11.45M |
| Rev Growth | — | +8.6% | -0.1% |
| Debt/Equity | 6.70 | 1.02 | 0.99 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |